Logan Coy Related postsSubstudy ASPEN-09-03: A Single-arm Phase 2 Study of Evorpacept with Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer (ASPEN-09-03), Protocol AT148009September 10, 2026A First-In-Human Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Locally Advanced or Metastatic Solid Tumors including NSCLC with MET AlterationsSeptember 11, 2026A Randomized, Multi-Center, Double-Blinded, Placebo-Controlled Trial of XEMBIFY plus Standard Medical Treatment vs Placebo to Prevent Infections in Hypogammaglobulinemia with CLL, Multiple Myeloma, and Non-Hodgkin LymphomaSeptember 11, 2026 Previous postA Phase 1b/2 Open-Label Study of APVO436 in Combination with Venetoclax and Azacitidine in Newly Diagnosed Acute Myeloid Leukemia (AML)Next postA Phase 1/2 Open-Label, Dose-Escalation Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Advanced, EGFR-Mutant, Metastatic NSCLC that Progressed after Osimertinib